Danaher Co. (NYSE:DHR) Holdings Reduced by Dynamic Advisor Solutions LLC

Dynamic Advisor Solutions LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 12.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,462 shares of the conglomerate’s stock after selling 913 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Danaher were worth $1,483,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Eclectic Associates Inc. ADV boosted its position in Danaher by 8.7% during the 4th quarter. Eclectic Associates Inc. ADV now owns 964 shares of the conglomerate’s stock worth $221,000 after acquiring an additional 77 shares during the period. CX Institutional lifted its holdings in Danaher by 2.1% in the fourth quarter. CX Institutional now owns 2,970 shares of the conglomerate’s stock worth $682,000 after purchasing an additional 62 shares during the period. Manitou Investment Management Ltd. grew its position in Danaher by 0.5% in the 4th quarter. Manitou Investment Management Ltd. now owns 92,685 shares of the conglomerate’s stock valued at $21,276,000 after buying an additional 481 shares in the last quarter. Hengehold Capital Management LLC increased its stake in Danaher by 30.3% during the 4th quarter. Hengehold Capital Management LLC now owns 2,340 shares of the conglomerate’s stock valued at $537,000 after buying an additional 544 shares during the period. Finally, True North Advisors LLC raised its position in shares of Danaher by 70.8% during the 4th quarter. True North Advisors LLC now owns 1,720 shares of the conglomerate’s stock worth $395,000 after buying an additional 713 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR opened at $245.95 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. The business’s 50-day moving average is $235.33 and its 200-day moving average is $253.45. Danaher Co. has a fifty-two week low of $225.42 and a fifty-two week high of $281.70.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research analyst reports. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Robert W. Baird dropped their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Royal Bank of Canada decreased their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Raymond James dropped their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Finally, TD Cowen lifted their price objective on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.